A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

• ClinicalTrials.gov Identifier: NCT01873534
• Recruitment Status: Terminated
• First Posted: June 10, 2013
• Last Update Posted: August 11, 2015
• Sponsor: FerruMax Pharmaceuticals, Inc.
• Collaborator: Davita Clinical Research
• Information provided by (Responsible Party): FerruMax Pharmaceuticals, Inc.

Study Description

Brief Summary:

The trial is an uncontrolled, open-label, parallel group clinical trial. Approximately 10 subjects per dose group in 3 groups will be treated twice weekly for a total of 9 doses, followed by a 4-week observation period. Eligible subjects who have Hgb ≥10.5 g/dL and have stable Hgb levels will start the washout period of one to eight weeks. During the washout period, 30 subjects whose Hgb are < 10.0 will complete the baseline assessment to confirm their eligibility. Eligible subjects will be randomly assigned to one of the 3 cohorts in a 1:1:1 ratio. Subjects will be admitted on the day of the first dose and stay in the clinic overnight for pharmacokinetic (PK) sampling after the first (day 1) and the last dose (day 29). FMX-8 will be administered as 30 min i.v. infusion. After the 29-day treatment period, the trial subjects will be observed for an additional 28 days to allow safety and immunogenicity assessments.

Condition or disease	Intervention/treatment	Phase
Anemia of Chronic Disease	Drug: FMX-8	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 6 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
• Study Start Date: June 2013
• Actual Primary Completion Date: March 2014
• Actual Study Completion Date: March 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: FMX-8 (0.5 mg/kg); 0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)	Drug: FMX-8; FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
Experimental: FMX-8 (5 mg/kg); 5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)	Drug: FMX-8; FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
Experimental: FMX-8 (15 mg/kg); 15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)	Drug: FMX-8; FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.

Outcome Measures

Primary Outcome Measures :

1. The proportion of subjects who achieve an increase in Hgb ≥ 1g/dL from the lowest Hgb concentration post erythropoietin-washout or continuing rise in Hgb concentration for two consecutive weeks [ Time Frame: Weekly for 8 weeks ]
2. Number and Severity of Adverse Events [ Time Frame: 8 weeks ]
3. Serum FMX-8 levels [ Time Frame: Dosing Days 1 and 29 ]
   Serum drug levels (pre-dose, and 25 minutes, 35 minutes, 1, 2, 4, 6, 10, 16 and 24 hrs post-dose) will be used to determine, for each dose, standard pK profiles
4. Number of Subjects with Positive Serum for Anti-Drug Antibodies [ Time Frame: At 36 and 57 days after first dose of FMX-8 ]

Secondary Outcome Measures :

1. Changes in Hgb in each dose group during the treatment and follow-up periods [ Time Frame: Weekly for 8 weeks ]
2. Proportion of subjects that achieve/maintain an absolute Hgb concentration of ≥ 10.0 g/dL for two consecutive weeks [ Time Frame: Weekly for 8 weeks ]
3. Time to beginning of steady increase of Hgb (for two consecutive weeks) [ Time Frame: Weekly for 8 weeks ]
4. Time to Hgb increase ≥1 g/dL [ Time Frame: Weekly for 8 weeks ]
5. Time to full recovery of Hgb to pre- erythropoietin-washout level [ Time Frame: Weekly for 8 weeks ]
6. Proportion of subjects needing erythropoietin rescue and length of time to start of rescue therapy [ Time Frame: Weekly for 8 weeks ]
7. Change of hepcidin and erythropoietin [ Time Frame: At weeks 2, 4, 6 and 8 from baseline ]
8. Changes in Serum Iron, Tsat and plasma Ferritin [ Time Frame: At weeks 2, 4, 6 and 8 compared to baseline ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female patients who are ≥18 years old
• Diagnosed with ESRD and are stable on hemodialysis for more than 3 months
• Maintained stable Hgb for ≥4 weeks prior to screening
• Two consecutive Hgb values ≥10.5 g/dL within 5 weeks of screening
• Body mass index (BMI) between 18 kg/m2 and 42 kg/m2, inclusive, based upon the latest height and weight
• Ferritin levels ≥100 mg/L or Tsat ≥20% or reticulocyte hemoglobin content (CHr) >25 at screening
• Reasonable clearances on dialysis (KT/V ≥1.0) on two prior determinations within 2.5 months
• Able to provide written informed consent
• Able to understand and follow all trial procedures
• Willing to use contraception as detailed in the protocol

Exclusion Criteria:

• Hgb remains unchanged without erythropoietin (<0.5 g/dL decrease during the 8 week maximum erythropoietin-washout period)
• Receipt of iron infusion after the initiation of erythropoietin washout
• Receipt of red blood cell transfusion within four weeks before screening
• Overt gastrointestinal bleeding or other bleeding episode that required transfusion within 2 months prior to screening
• Infection necessitating antibiotic or anti-viral treatment within a month prior to screening
• Requirement for Coumadin (warfarin), Pradaxa or Xarelto
• Hemoglobinopathies such as homozygous sickle-cell disease or thalassemias of all types
• Active hemolysis or chronic hypoxia
• Active malignant diseases (except non-melanoma skin cancer) or life expectancy less than 6 months
• Chronic, uncontrolled or symptomatic inflammatory disease or non-renal cause of anemia such as rheumatoid arthritis, systemic lupus erythematosus, HIV, or systemic acute infection
• On immunosuppressive therapeutics
• Chronic congestive heart failure (New York Heart Association Class III, IV)
• Significant hypertension (≥90 diastolic) based on a sitting diastolic blood pressure at screening
• Kidney transplant within the past year: patients who are off immunosuppressive agents following a failed transplant are eligible for the trial
• End-stage liver disease
• Known hypersensitivity to recombinant protein therapies
• Female patients who are pregnant or breast feeding
• Previous exposure to FMX-8
• Exposure to Omontys® or Hematide® (peginesatide) anemia treatment within the past 6 months
• Treatment with Aranesp® (darbepoetin alpha) within the past 4 weeks
• Uncontrolled hyperparathyroidism (PTH >750) based upon latest PTH determination within the past 4 months
• Inability to comply with the trial scheduled visits

Contacts and Locations

Locations

United States, Colorado

DaVita Arvada Dialysis Center

Arvada, Colorado, United States, 80005

United States, Minnesota

DaVita Minneapolis Dialysis Unit

Minneapolis, Minnesota, United States, 55404

Sponsors and Collaborators

FerruMax Pharmaceuticals, Inc.

Davita Clinical Research

Investigators

• Study Chair: Leslie Fang, MD, PhD; FerruMax Pharmaceuticals, Inc.

More Information

• Responsible Party: FerruMax Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT01873534 History of Changes
• Other Study ID Numbers: FX-C-402
• First Posted: June 10, 2013
• Last Update Posted: August 11, 2015
• Last Verified: July 2015

Keywords provided by FerruMax Pharmaceuticals, Inc.:

Anemia

Additional relevant MeSH terms:

Anemia; Chronic Disease; Hematologic Diseases; Disease Attributes; Pathologic Processes